ESMO 2019 Updated IMpower110 Trial Results: With Consistent OS/PFS Improvement, Atezolizumab Is a New 1st-Line Treatment Option for PD-L1-High Stage IV NSCLC
By
Yale Cancer Center
FEATURING
Roy Herbst
By
Yale Cancer Center
FEATURING
Roy Herbst
Login to view comments.
Click here to Login